Spyre Therapeutics Announces Grants of Inducement Awards

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) granted inducement stock options totaling 30,200 shares to five non-executive employees under its 2018 Equity Inducement Plan.

Approved on Feb 2, 2026, the options have a 10-year term, $32.75 exercise price (Feb 2 close) and vest 25% after one year then monthly at 1/48th, subject to continuous service.

News Market Reaction – SYRE

-3.30%

-3.30% Session close to close

In the Feb 9 session, SYRE declined 3.30%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a new 30,200-share stock option grant to five non‑executive employees unde...

Analysis

This announcement details a new 30,200-share stock option grant to five non‑executive employees under Spyre’s 2018 Equity Inducement Plan, with a $32.75 exercise price and standard four‑year vesting. It continues a pattern of option-based hiring incentives seen in multiple prior releases. Investors monitoring the story may focus more on upcoming clinical catalysts and previously disclosed 2026 proof‑of‑concept readouts than on this routine compensation item.

Key Figures

Inducement options granted: 30,200 shares Exercise price: $32.75 Option term: 10 years +2 more

5 metrics

Inducement options granted 30,200 shares Aggregate stock options to five non-executive employees under 2018 Plan

Exercise price $32.75 Option strike price, equal to Feb 2, 2026 Nasdaq closing price

Option term 10 years Duration of newly granted stock options

Initial vesting 1/4 of shares Vests on first anniversary of each employee’s start date

Ongoing vesting rate 1/48 monthly Remaining shares vest monthly after first anniversary, subject to service

Historical Context

5 past events · Latest: Jan 23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 23	Inducement award grant	Neutral	+0.8%	Large option grant to new Chief Commercial Officer under 2018 inducement plan.
Jan 12	Pipeline/corporate update	Positive	+7.2%	Outlined six 2026 proof-of-concept readouts and highlighted strong cash balance.
Jan 08	Inducement award grants	Neutral	+1.6%	Options for 42,000 shares to six non-executive employees as hiring inducements.
Dec 05	Inducement award grants	Neutral	+3.5%	20,300-option inducement awards to two non-executive employees under 2018 plan.
Nov 07	Inducement award grant	Neutral	-1.5%	19,600-share option grant to a non-executive employee under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Repeated inducement award announcements have generally coincided with modestly positive or mixed price reactions, suggesting these HR-related updates have not been major standalone catalysts.

Recent Company History

Over the past few months, Spyre has repeatedly used its 2018 Equity Inducement Plan to grant options to new employees, with prior announcements on Nov 7, 2025, Dec 5, 2025, Jan 8, 2026, and Jan 23, 2026. These were usually tied to non‑executive hires or a new commercial leader. Alongside this, a January update detailed six planned 2026 proof‑of‑concept readouts and substantial cash resources, which drew the strongest positive reaction, framing today’s grant as part of an ongoing build‑out rather than a new strategic shift.

Key Terms

equity inducement awards, Nasdaq Listing Rule 5635(c)(4), exercise price

3 terms

equity inducement awards financial

"shares of common stock of Spyre to five non-executive employees as equity inducement awards"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"a 10-year term and an exercise price equal to $32.75, the closing price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 30,200 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on February 2, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $32.75, the closing price per share of Spyre's common stock as reported by Nasdaq on February 2, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The stock options are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors :
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

What did Spyre Therapeutics (SYRE) announce about inducement stock options on February 6, 2026?

Spyre granted an aggregate of 30,200 stock options to five non-executive employees as inducement awards. According to the company, the grants were approved Feb 2, 2026 and are subject to the 2018 Equity Inducement Plan.

What are the key terms of the Spyre (SYRE) option grants approved Feb 2, 2026?

The options carry a 10-year term and an exercise price of $32.75 per share. According to the company, $32.75 equals the Nasdaq closing price on Feb 2, 2026 for Spyre common stock.

How do the Spyre (SYRE) inducement options vest for new employees?

Vesting is 25% on the first anniversary and then monthly at 1/48th thereafter. According to the company, vesting is contingent on continuous service through each applicable vesting date.

Why did Spyre (SYRE) grant inducement awards under the 2018 Plan?

The awards were approved as equity inducements to facilitate employee hiring and acceptance. According to the company, the grants were material to each employee's acceptance per Nasdaq Listing Rule 5635(c)(4).

What is the immediate shareholder impact of the Spyre (SYRE) 30,200 option grant?

The company issued options representing 30,200 shares exercisable at $32.75, but immediate dilution depends on future exercises. According to the company, the options follow plan terms and standard vesting conditions.